Quantum-Si Highlights Major Technical Advances, Next-Generation Platform Architecture and New Proteomic Applications at Investor & Analyst Event
Quantum-Si (QSI) announced major technical advances at its Investor & Analyst event, introducing two key platforms: Platinum Pro and Proteus. Platinum Pro, launching in H1 2025, will offer streamlined workflow, reduced processing time, and custom application development. Proteus, launching in H2 2026, represents a new proteomics platform featuring ultrasensitive detection, automated liquid handling, and rapid sequencing chemistry with 90-minute run times.
The company announced strategic partnerships with Avantor for distribution in US/Canada, NVIDIA for enhanced data processing, SkyWater for consumable platform development, and Planet Innovation for manufacturing support.
Quantum-Si (QSI) ha annunciato importanti avanzamenti tecnici durante il suo evento per investitori e analisti, presentando due piattaforme chiave: Platinum Pro e Proteus. Platinum Pro, che sar脿 lanciato nel primo semestre del 2025, offrir脿 un flusso di lavoro semplificato, tempi di elaborazione ridotti e sviluppo di applicazioni personalizzate. Proteus, che sar脿 lanciato nel secondo semestre del 2026, rappresenta una nuova piattaforma di proteomica con rilevamento ultrasensibile, gestione automatizzata dei liquidi e chimica di sequenziamento rapida con cicli di 90 minuti.
L'azienda ha annunciato alleanze strategiche con Avantor per la distribuzione negli Stati Uniti e Canada, NVIDIA per un'elaborazione dei dati migliorata, SkyWater per lo sviluppo di piattaforme di consumabili e Planet Innovation per il supporto alla produzione.
Quantum-Si (QSI) anunci贸 importantes avances t茅cnicos en su evento de Inversores y Analistas, presentando dos plataformas clave: Platinum Pro y Proteus. Platinum Pro, que se lanzar谩 en el primer semestre de 2025, ofrecer谩 un flujo de trabajo simplificado, reducci贸n del tiempo de procesamiento y desarrollo de aplicaciones personalizadas. Proteus, que se lanzar谩 en el segundo semestre de 2026, representa una nueva plataforma de prote贸mica que cuenta con detecci贸n ultrasensible, manejo automatizado de l铆quidos y qu铆mica de secuenciaci贸n r谩pida con tiempos de ejecuci贸n de 90 minutos.
La empresa anunci贸 asociaciones estrat茅gicas con Avantor para distribuci贸n en EE.UU./Canad谩, NVIDIA para un procesamiento de datos mejorado, SkyWater para el desarrollo de plataformas consumibles y Planet Innovation para apoyo a la fabricaci贸n.
Quantum-Si (QSI)電 韴瀽鞛 氚 攵勳劃臧 頄夓偓鞐愳劀 欤检殧 旮办垹 氚滌爠鞚 氚滍憸頃橂┌ 霊 臧歆 頃奠嫭 頂岆灚韽检澑 Platinum Pro鞕赌 Proteus毳 靻岅皽頄堨姷雼堧嫟. Platinum Pro電 2025雲 靸侂皹旮 於滌嫓 鞓堨爼鞚措┌, 臧勳唽頇旊悳 鞛戩梾 頋愲, 雼稌霅 觳橂Μ 鞁滉皠 氚 毵烄钉順 鞎犿攲毽紑鞚挫厴 臧滊皽鞚 鞝滉车頃╇媹雼. Proteus電 2026雲 頃橂皹旮 於滌嫓霅橂┌, 齑堧臧 韮愳, 鞛愲彊頇旊悳 鞎§泊 觳橂Μ 氚 90攵 鞁ろ枆 鞁滉皠鞚 鞁犾啀頃 鞁滍鞁 頇旐暀鞚 韸轨鞙茧 頃橂姅 靸堧鞖 雼氨歆堨泊 頂岆灚韽检潉 雮橅儉雰呺媹雼.
須岇偓電 氙戈淡/旌愲倶雼 鞙犿喌鞚 鞙勴暅 Avantor, 雿办澊韯 觳橂Μ毳 鞙勴暅 NVIDIA, 靻岆箘鞛 頂岆灚韽 臧滊皽鞚 鞙勴暅 SkyWater, 鞝滌“ 歆鞗愳潉 鞙勴暅 Planet Innovation瓿 鞝勲灥鞝 韺岉姼雱堨嫮鞚 觳搓舶頄堧嫟瓿 氚滍憸頄堨姷雼堧嫟.
Quantum-Si (QSI) a annonc茅 d'importantes avanc茅es techniques lors de son 茅v茅nement pour investisseurs et analystes, en pr茅sentant deux plateformes cl茅s : Platinum Pro et Proteus. Platinum Pro, qui sera lanc茅 au premier semestre 2025, offrira un flux de travail simplifi茅, une r茅duction du temps de traitement et un d茅veloppement d'applications personnalis茅es. Proteus, qui sera lanc茅 au second semestre 2026, repr茅sente une nouvelle plateforme de prot茅omique avec d茅tection ultrasensible, gestion automatis茅e des liquides et chimie de s茅quen莽age rapide avec des temps d'ex茅cution de 90 minutes.
L'entreprise a annonc茅 des partenariats strat茅giques avec Avantor pour la distribution aux 脡tats-Unis/Canada, NVIDIA pour un traitement de donn茅es am茅lior茅, SkyWater pour le d茅veloppement de plateformes de consommables et Planet Innovation pour le soutien 脿 la fabrication.
Quantum-Si (QSI) gab bedeutende technische Fortschritte bei seiner Veranstaltung f眉r Investoren und Analysten bekannt und stellte zwei Schl眉sselplattformen vor: Platinum Pro und Proteus. Platinum Pro, das im ersten Halbjahr 2025 auf den Markt kommen wird, bietet einen optimierten Arbeitsablauf, verk眉rzte Verarbeitungszeiten und individuelle Anwendungsentwicklung. Proteus, das im zweiten Halbjahr 2026 vorgestellt wird, stellt eine neue Proteomics-Plattform dar, die ultrasensible Detektion, automatisierte Fl眉ssigkeitsbehandlung und schnelle Sequenzierung mit 90-min眉tiger Laufzeit bietet.
Das Unternehmen gab strategische Partnerschaften mit Avantor f眉r den Vertrieb in den USA/Kanada, NVIDIA f眉r verbesserte Datenverarbeitung, SkyWater f眉r die Entwicklung von Verbrauchsmaterialplattformen und Planet Innovation f眉r Produktionsunterst眉tzung bekannt.
- Launch of Platinum Pro platform in H1 2025 with enhanced capabilities
- Development of Proteus platform with potential for billions of sequencing reads
- Strategic partnership with Avantor for US/Canada distribution
- Cost reduction through elimination of semiconductor chip technology in Proteus
- Expected improvement in consumable margin profile
- Extended timeline for Proteus launch (H2 2026)
- Significant R&D investment required for new platform development
Insights
This announcement reveals significant strategic developments for Quantum-Si's proteomics technology roadmap. The Platinum Pro platform, launching H1 2025, brings workflow improvements and customization capabilities critical for biopharma customers. More transformative is the Proteus platform (H2 2026), which represents a fundamental architecture shift that could dramatically improve cost economics through elimination of semiconductor chip dependency.
The strategic partnerships are particularly noteworthy:
- Avantor distribution agreement expands market reach
- NVIDIA collaboration addresses computational bottlenecks
- SkyWater and Planet Innovation partnerships de-risk manufacturing
The commercial strategy demonstrates strong market positioning. The Avantor distribution partnership provides access to an established sales channel in North America, while the 'Pro Mode' feature targets the lucrative biopharma segment. The planned technical capabilities of Proteus - including 90-minute run times and automated liquid handling - address key market demands for higher throughput and easier workflow.
The shift from semiconductor chips to a more cost-effective consumable model could significantly improve gross margins and unit economics. However, the 2026 launch timeline for Proteus means near-term revenue growth will depend on Platinum Pro's market reception in 2025.
Provides Update on the Company鈥檚 Innovation Roadmap & New Development Partnerships
Highlights new Distribution Agreement with Avantor in the
Quantum-Si鈥檚 Management team announced Platinum鈩 Pro, the Company鈥檚 evolution of Platinum, as well as Proteus鈩, the Company鈥檚 new cutting-edge proteomics platform of the future, that is now under development.
鈥淲e are very excited to have this opportunity to unveil the rapid innovation that we have achieved at Quantum-Si over the last 15 months since our R&D realignment process last August,鈥 said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si. 鈥淔irst, the launch of Platinum Pro will provide meaningful enhancements over our current Platinum platform in relation to workflow, applications and onboard software analysis.鈥
Hawkins continued, 鈥淪econd and most important, we believe the development and launch of our Proteus platform is set to redefine proteomics with unprecedented output per sample, application flexibility and automation. We believe Proteus is the foundational platform to enable billions of sequencing reads and eventually de novo sequencing of the proteome. Finally, with this innovation path, we also believe Proteus and future related innovations will open broad new markets for diverse applications in protein analysis, driving increased revenue growth that will create significant value for our shareholders. With these technology advancements and partnerships in place, we believe we will be able to further extend our leadership position in next-generation protein sequencing while also extending into other areas of proteomics more generally.鈥
Platinum Pro: Exciting Progress of Enhanced Protein Sequencing
The Company announced a next-generation Platinum system, the Platinum Pro, which is scheduled to launch in the first half of 2025. Platinum Pro will provide a streamlined workflow, reducing hands-on time, and faster processing time. Platinum Pro will enable data analysis to be performed locally or using the cloud and will also offer a 鈥楶ro Mode鈥, which allows for custom application development, a compelling feature for biopharmaceutical customers.
Proteus: The Proteomics Platform of the Future
The Company also announced the development of a new cutting-edge proteomics platform, Proteus, which is scheduled to launch in the second half of 2026. Proteus will enable a broad range of capabilities for proteomic analysis including ultrasensitive detection of proteoforms, unbiased interrogation of high complexity samples, and new rapid sequencing chemistry that can reduce the run time per sample to 90 minutes or less. The new Proteus platform will also include automated liquid handling to reduce hands-on time and increase sample throughput.
The Company expects that Proteus will be the foundational platform to increase the output of sequencing reads from tens of millions of reads per sample at launch to billions of reads per sample over time. Further, the Company anticipates that Proteus, combined with other technology development initiatives, will enable de novo sequencing in the future.
Proteus represents a significant transformation to the Company鈥檚 core technology architecture, moving the optics into the instrument and allowing the Company to make a low cost, scalable consumable and eliminating the higher cost semi-conductor chip technology, dramatically increasing the consumable margin profile for the future.
Most of the Proteus design and planned capabilities leverage existing proven technologies already in place at the Company, including consumable surface chemistry, sequencing chemistry, recognition technology and optical technology; all of which significantly de-risks the development timeline.
New Partnerships
In connection with the development of Proteus, the Company has announced new partnerships and collaborations to accelerate and further de-risk the development and hardware platform delivery process as well a new partnership for commercial execution in
Avantor: The Company announced it has entered into an agreement with Avantor庐 to distribute the Company鈥檚 proteomics solutions in the
NVIDIA: The Company has entered into a collaboration with NVIDIA to significantly enhance data processing speeds to handle the increased data volume from Proteus by leveraging NVIDIA鈥檚 accelerated computing. With this collaboration and other development milestones, the Company expects processing time to be reduced to 90 minutes. ().
SkyWater: The Company announced an expanded partnership with SkyWater Technologies for development of Proteus鈥 consumable platform to increase the output per sample to unprecedented levels. ().
Planet Innovation: The Company has partnered with Planet Innovation on the development and manufacturing of Proteus. Planet Innovation has a team of over four hundred people with expertise across design, development and manufacturing of scientific instrumentation and medical devices and has a proven track record of rapid development and on time product delivery. Partnering with Planet Innovation will allow the Company to further de-risk development of key components of Proteus on the path to delivery to the market in the second half of 2026. ().
Webcast Replay
A replay of the Investor & Analyst Day event is available through the Investor Relations section of Quantum-Si鈥檚 website at . The archived webcast will be available for at least 90 days.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company鈩, is focused on revolutionizing the growing field of proteomics. The Company鈥檚 Platinum庐 instrument enables Next-Generation Protein Sequencing鈩 that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at or follow us on or .
Forward Looking Statements
This press release includes 鈥渇orward-looking statements鈥 within the meaning of the 鈥渟afe harbor鈥 provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as 鈥渆xpect,鈥 鈥渆stimate,鈥 鈥減roject,鈥 鈥渂udget,鈥 鈥渇orecast,鈥 鈥渁nticipate,鈥 鈥渋ntend,鈥 鈥減lan,鈥 鈥渕ay,鈥 鈥渨ill,鈥 鈥渃ould,鈥 鈥渟hould,鈥 鈥渂elieves,鈥 鈥減redicts,鈥 鈥減otential,鈥 鈥渃ontinue,鈥 and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company鈥檚 expectations with respect to future performance and development and commercialization of products and services, its anticipated cash runway and its financial guidance for the full year 2024. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company鈥檚 control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company鈥檚 Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company鈥檚 ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company鈥檚 product development and commercialization activities; the commercialization and adoption of the Company鈥檚 existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company鈥檚 commercialized Platinum庐 protein sequencing instrument and kits and the Company鈥檚 other products once commercialized; the Company鈥檚 ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company鈥檚 ability to identify, in-license or acquire additional technology; the Company鈥檚 ability to maintain its existing lease, license, manufacture and supply agreements; the Company鈥檚 ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company鈥檚 products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company鈥檚 estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company鈥檚 financial performance; and other risks and uncertainties described under 鈥淩isk Factors鈥 in the Company鈥檚 most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in the Company鈥檚 other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
View source version on businesswire.com:
Investor
Doug Farrell, VP, Investor Relations
ir@quantum-si.com
Media
Katherine Atkinson, SVP, Commercial Marketing
media@quantum-si.com
Source: Quantum-Si Incorporated
FAQ
When will Quantum-Si (QSI) launch the Platinum Pro platform?
What are the key features of QSI's new Proteus platform?
Who are Quantum-Si's new strategic partners for the Proteus platform?
How will QSI's Proteus platform improve cost efficiency?
